Ab­b­Vie, J&J block­buster Im­bru­vi­ca rakes in 11th FDA ap­proval, as com­peti­tors work on erod­ing fran­chise

Ab­b­Vie and J&J’s mar­ket-lead­ing Im­bru­vi­ca, the orig­i­nal BTK in­hibitor, con­tin­ues to rake in ap­provals, while com­pe­ti­tion in the class of drugs heats up.

On Tues­day, the drug se­cured its 11th FDA ap­proval. Im­bru­vi­ca in com­bi­na­tion with Roche’s rit­ux­imab has been sanc­tioned for use as the first line of de­fense in pa­tients with chron­ic lym­pho­cyt­ic leukemia (CLL) or small lym­pho­cyt­ic lym­phoma (SLL).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER